Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

Capranico G, Kohn KW, Pommier Y.

Nucleic Acids Res. 1990 Nov 25;18(22):6611-9.

2.

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Pommier Y, Capranico G, Orr A, Kohn KW.

Nucleic Acids Res. 1991 Nov 11;19(21):5973-80. Erratum in: Nucleic Acids Res 1991 Dec 25;19(24):7003.

3.

Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs.

Pommier Y, Capranico G, Orr A, Kohn KW.

J Mol Biol. 1991 Dec 20;222(4):909-24.

PMID:
1662289
4.

Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin.

Jaxel C, Kohn KW, Pommier Y.

Nucleic Acids Res. 1988 Dec 9;16(23):11157-70.

5.
6.

Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers.

Capranico G, Tinelli S, Zunino F, Kohn KW, Pommier Y.

Biochemistry. 1993 Jan 12;32(1):145-52.

PMID:
8380330
7.

Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

De Isabella P, Zunino F, Capranico G.

Nucleic Acids Res. 1995 Jan 25;23(2):223-9.

9.
10.

DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.

Seo J, Lee HS, Lee M, Kim M, Shin CG.

Arch Pharm Res. 2004 Jan;27(1):77-82.

PMID:
14969343
11.

Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.

Borgnetto ME, Zunino F, Tinelli S, Kas E, Capranico G.

Cancer Res. 1996 Apr 15;56(8):1855-62.

12.

Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.

Capranico G, De Isabella P, Tinelli S, Bigioni M, Zunino F.

Biochemistry. 1993 Mar 30;32(12):3038-46.

PMID:
8384486
13.

Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

Fossé P, René B, Le Bret M, Paoletti C, Saucier JM.

Nucleic Acids Res. 1991 Jun 11;19(11):2861-8.

14.

Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin.

Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y.

J Biol Chem. 1991 Oct 25;266(30):20418-23.

15.
16.

In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin.

Yang L, Rowe TC, Nelson EM, Liu LF.

Cell. 1985 May;41(1):127-32.

PMID:
2986841
17.

Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.

De Isabella P, Capranico G, Palumbo M, Sissi C, Krapcho AP, Zunino F.

Mol Pharmacol. 1993 May;43(5):715-21.

PMID:
8388987
18.

Recognition sites of eukaryotic DNA topoisomerase I: DNA nucleotide sequencing analysis of topo I cleavage sites on SV40 DNA.

Edwards KA, Halligan BD, Davis JL, Nivera NL, Liu LF.

Nucleic Acids Res. 1982 Apr 24;10(8):2565-76.

19.

Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.

Bigioni M, Zunino F, Tinelli S, Austin CA, Willmore E, Capranico G.

Biochemistry. 1996 Jan 9;35(1):153-9.

PMID:
8555169
20.

Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y.

Mol Pharmacol. 1990 Jul;38(1):38-45.

PMID:
2164630

Supplemental Content

Support Center